Singh Sanjay, Soni Rajeev, Rawat Manoj Kumar, Jain Achint, Deshpande Shripad Bhimarao, Singh Sanjeev Kumar, Muthu Madaswamy Sona
Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi-221005, India.
Chem Pharm Bull (Tokyo). 2010 Mar;58(3):307-11. doi: 10.1248/cpb.58.307.
The aim of present study was to prepare and evaluate buccal bioadhesive films of salbutamol sulphate (SS) for the treatment of asthma. The films were designed to release the drug for a prolonged period of time so as to reduce the frequency of administration of the available conventional dosage forms of SS. The different proportions of sodium carboxymethylcellulose (SCMC) and Carbopol 940P (CP 940P) were used for the preparation of films. Carbopol was used to incorporate the desired bioadhesiveness in the films. The films were prepared by solvent casting method and evaluated for bioadhesion, in vitro drug release and anti asthmatic effect (bronchoprotection) in histamine induced bronchospasm of guinea pigs. In vitro drug release from the film was determined using a modified Franz diffusion cell while bioadhesiveness was evaluated with a modified two-arm balance using guinea pig buccal mucosa as a model tissue. Films containing SCMC : CP 940P ratio of 76 : 24 was found to be the best with moderate swelling along with favorable bioadhesion force and in vitro drug release. The drug release mechanism was found to follow non-Fickian diffusion as release mechanism. The prolonged in vivo effect (bronchoprotection) obtained from the buccal bioadhesive film of SS administered via buccal route may improve the treatment of asthmatic disorders by reducing the frequency of administration which is associated with the tolerance effect of SS. Additionally for the clinical benefit, it is also expected to reduce the major adverse effects of SS such as tachycardia and arrhythmias via buccal absorption.
本研究的目的是制备并评估用于治疗哮喘的硫酸沙丁胺醇(SS)口腔生物黏附膜。这些膜被设计用于长时间释放药物,以减少现有SS传统剂型的给药频率。使用不同比例的羧甲基纤维素钠(SCMC)和卡波姆940P(CP 940P)来制备膜。卡波姆用于使膜具有所需的生物黏附性。通过溶剂浇铸法制备膜,并在组胺诱导的豚鼠支气管痉挛中评估其生物黏附性、体外药物释放和抗哮喘作用(支气管保护作用)。使用改良的Franz扩散池测定膜的体外药物释放,同时以豚鼠口腔黏膜作为模型组织,用改良的双臂天平评估生物黏附性。发现含有SCMC:CP 940P比例为76:24的膜最佳,具有适度的溶胀以及良好的生物黏附力和体外药物释放。发现药物释放机制遵循非Fickian扩散作为释放机制。通过口腔途径给药的SS口腔生物黏附膜获得的延长的体内作用(支气管保护作用),可能通过减少与SS耐受性效应相关的给药频率来改善哮喘疾病的治疗。此外,为了临床益处,还预期通过口腔吸收减少SS的主要不良反应,如心动过速和心律失常。